Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
<p>Supplementary Figure 5: Copy number variants in the three main glioblastoma groups according to classifier v12.5. A Copy number variants in all patients combined (n = 295), B in RTK1 tumors (n = 89), C in RTK2 tumors (n = 140) and D in MES tumors (n = 66). PDGFRA amplifications are enriched...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Daljnji autori: | , , , , , , , , , , , , , , , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
| _version_ | 1849927632748019712 |
|---|---|
| author | Tobias Kessler (17079209) |
| author2 | Daniel Schrimpf (17079212) Laura Doerner (17079215) Ling Hai (17079218) Leon D. Kaulen (17079221) Jakob Ito (17079224) Martin van den Bent (17079227) Martin Taphoorn (17079230) Alba A. Brandes (17079233) Ahmed Idbaih (17079236) Julien Dômont (17079239) Paul M. Clement (15044256) Mario Campone (15027156) Martin Bendszus (17079242) Andreas von Deimling (15037904) Felix Sahm (15097382) Michael Platten (15018165) Wolfgang Wick (15018168) Antje Wick (17079245) |
| author2_role | author author author author author author author author author author author author author author author author author author |
| author_facet | Tobias Kessler (17079209) Daniel Schrimpf (17079212) Laura Doerner (17079215) Ling Hai (17079218) Leon D. Kaulen (17079221) Jakob Ito (17079224) Martin van den Bent (17079227) Martin Taphoorn (17079230) Alba A. Brandes (17079233) Ahmed Idbaih (17079236) Julien Dômont (17079239) Paul M. Clement (15044256) Mario Campone (15027156) Martin Bendszus (17079242) Andreas von Deimling (15037904) Felix Sahm (15097382) Michael Platten (15018165) Wolfgang Wick (15018168) Antje Wick (17079245) |
| author_role | author |
| dc.creator.none.fl_str_mv | Tobias Kessler (17079209) Daniel Schrimpf (17079212) Laura Doerner (17079215) Ling Hai (17079218) Leon D. Kaulen (17079221) Jakob Ito (17079224) Martin van den Bent (17079227) Martin Taphoorn (17079230) Alba A. Brandes (17079233) Ahmed Idbaih (17079236) Julien Dômont (17079239) Paul M. Clement (15044256) Mario Campone (15027156) Martin Bendszus (17079242) Andreas von Deimling (15037904) Felix Sahm (15097382) Michael Platten (15018165) Wolfgang Wick (15018168) Antje Wick (17079245) |
| dc.date.none.fl_str_mv | 2025-11-25T13:22:33Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30708532 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S5_from_Prognostic_Markers_of_DNA_Methylation_and_Next-Generation_Sequencing_in_Progressive_Glioblastoma_from_the_EORTC-26101_Trial/30708532 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Epigenetic biomarkers Prognostic biomarkers CNS Cancers Gliomas, Glioblastomas Computational Methods Sequence analysis Precision Medicine |
| dc.title.none.fl_str_mv | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplementary Figure 5: Copy number variants in the three main glioblastoma groups according to classifier v12.5. A Copy number variants in all patients combined (n = 295), B in RTK1 tumors (n = 89), C in RTK2 tumors (n = 140) and D in MES tumors (n = 66). PDGFRA amplifications are enriched in RTK1 tumors and gains of chromosomes 19 and 20 are enriched in RTK2 tumors.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_d70fa0209536af3d8b036d89ea98dc55 |
| identifier_str_mv | 10.1158/1078-0432.30708532 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30708532 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 TrialTobias Kessler (17079209)Daniel Schrimpf (17079212)Laura Doerner (17079215)Ling Hai (17079218)Leon D. Kaulen (17079221)Jakob Ito (17079224)Martin van den Bent (17079227)Martin Taphoorn (17079230)Alba A. Brandes (17079233)Ahmed Idbaih (17079236)Julien Dômont (17079239)Paul M. Clement (15044256)Mario Campone (15027156)Martin Bendszus (17079242)Andreas von Deimling (15037904)Felix Sahm (15097382)Michael Platten (15018165)Wolfgang Wick (15018168)Antje Wick (17079245)CancerCancer Detection and DiagnosisClinical Research and TrialsMethods and TechnologyBiomarkersEpigenetic biomarkersPrognostic biomarkersCNS CancersGliomas, GlioblastomasComputational MethodsSequence analysisPrecision Medicine<p>Supplementary Figure 5: Copy number variants in the three main glioblastoma groups according to classifier v12.5. A Copy number variants in all patients combined (n = 295), B in RTK1 tumors (n = 89), C in RTK2 tumors (n = 140) and D in MES tumors (n = 66). PDGFRA amplifications are enriched in RTK1 tumors and gains of chromosomes 19 and 20 are enriched in RTK2 tumors.</p>2025-11-25T13:22:33ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30708532https://figshare.com/articles/figure/Supplementary_Figure_S5_from_Prognostic_Markers_of_DNA_Methylation_and_Next-Generation_Sequencing_in_Progressive_Glioblastoma_from_the_EORTC-26101_Trial/30708532CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307085322025-11-25T13:22:33Z |
| spellingShingle | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial Tobias Kessler (17079209) Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Epigenetic biomarkers Prognostic biomarkers CNS Cancers Gliomas, Glioblastomas Computational Methods Sequence analysis Precision Medicine |
| status_str | publishedVersion |
| title | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| title_full | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| title_fullStr | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| title_full_unstemmed | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| title_short | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| title_sort | Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial |
| topic | Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Epigenetic biomarkers Prognostic biomarkers CNS Cancers Gliomas, Glioblastomas Computational Methods Sequence analysis Precision Medicine |